Alloreactive Donor-Derived NK Cells Preferentially Target AML Blasts, T Cells, and Antigen Presenting Cells (APC) Remaining in the Recipient After Conditioning for Transplantation. Recipients of alloreactive NK demonstrate lower rates of acute GVHD, graft rejection, leukemic relapse, and death after transplantation compared with recipients of non-alloreactive NK.